A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.

[1]  C. Andrewes,et al.  Observations on Anti-Phage Sera. I: “The Percentage Law” , 1933 .

[2]  A. Frank,et al.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.

[3]  J. Hierholzer,et al.  Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay , 1985, Journal of clinical microbiology.

[4]  M. Perkins,et al.  Primary respiratory syncytial virus infection in mice , 1988, Journal of medical virology.

[5]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[6]  P. Collins,et al.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. , 2000, Virology.

[7]  Q. Sattentau,et al.  Mechanisms of virus neutralization by antibody. , 2001, Current topics in microbiology and immunology.

[8]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.

[9]  R. Doms,et al.  A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. , 2006, Virology.

[10]  B. Graham,et al.  Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis , 2007, Journal of Virology.

[11]  M. Fay,et al.  A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. , 2007, The Journal of infectious diseases.

[12]  J. Mascola,et al.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.

[13]  T. Pierson,et al.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. , 2009, Virology.